In vitro efficacy of intralesional Collagenase Clostridium Histolyticum for the treatment of calcified Peyronie's disease plaques.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
31 Jul 2023
31 Jul 2023
Historique:
received:
22
01
2023
accepted:
18
07
2023
revised:
11
07
2023
medline:
1
8
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
aheadofprint
Résumé
Peyronie's disease (PD) is defined by penile plaque formation and curvature causing sexual dysfunction. The only FDA-approved intralesional treatment is Collagenase Clostridium histolyticum (CCh). CCh contains two collagenases, AUX1 and AUXII, that break down the type I and type III collagen contained in plaques, leading to plaque dissolution and reduction in penile curvature. Peyronie's plaques, however, also contain fibrin and calcium, which CCh cannot digest. It is unclear if plaque calcification prevents CCh from breaking down plaques. We collected ten tissue samples: five calcified penile plaques and five control samples of corpus cavernosum. They were incubated in CCh or PBS. Soluble collagen measurements and collagen staining assays were completed to measure tissue breakdown. Calcified plaques incubated in CCh showed significantly higher levels of soluble collagen (301.07 ug ± 21.28 vs. PBS: 32.82 ug ± 3.68, p = 0.02), and significantly lower levels of collagen (type I and III) compared to tissues incubated in PBS (0.12 ± 0.08, vs. 0.44 ± 0.17, p = 0.002). When comparing different tissues (calcified vs. control) incubated in CCh and PBS solutions, there were no significant differences in collagen staining or breakdown. Although higher collagen staining was seen in the calcified group, soluble collagen showed no significant differences between control and calcified tissues in the CCh group (control: 0.08 ± 0.02 vs. calcified: 0.17 ± 0.09, p = 0.08) or the PBS group (control: 0.50 ± 0.23 vs. calcified: 0.39 ± 0.39, p = 0.23). CCh exposure led to significantly more tissue breakdown in both tissue groups when compared to PBS however, there was no significant difference in plaque digestion found between calcified and control tissue exposed to CCh or PBS. This suggests that plaque calcification does not affect the action of CCh. Further research into CCh for calcified plaques is necessary to inform clinicians as to the optimal management of this population.
Identifiants
pubmed: 37524836
doi: 10.1038/s41443-023-00742-0
pii: 10.1038/s41443-023-00742-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS One. 2016;11:e0150157.
doi: 10.1371/journal.pone.0150157
pubmed: 26907743
pmcid: 4764365
Hartzell R. Psychosexual symptoms and treatment of Peyronie’s disease within a collaborative care model. Sex Med. 2014;2:168–77.
doi: 10.1002/sm2.45
pubmed: 25548648
pmcid: 4272248
Krakhotkin DV, Chernylovskyi VA, Mottrie A, Greco F, Bugaev RA. New insights into the pathogenesis of Peyronie’s disease: a narrative review. Chronic Dis Transl Med. 2020;6:165–81.
pubmed: 32885153
pmcid: 7451633
Hatfield BS, King CR, Udager AM, Williamson SR, Gandhi JS, Amin MB, et al. Peyronie disease: a clinicopathologic study of 71 cases with emphasis on histopathologic patterns and prevalent metaplastic ossification. Hum Pathol. 2020;104:9–17.
doi: 10.1016/j.humpath.2020.07.013
pubmed: 32681945
Hoy SM. Collagenase clostridium histolyticum: a review in Peyronie’s disease. Clin Drug Investig. 2020;40:83–92.
doi: 10.1007/s40261-019-00867-5
pubmed: 31628593
XIAFLEX® (collagenase clostridium histolyticum). [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125338s109lbl.pdf .
Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L. Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie’s disease. Urology. 2018;119:109–14.
doi: 10.1016/j.urology.2018.06.003
pubmed: 29908867
Levine L, Rybak J, Corder C, Farrel MR. Peyronie’s disease plaque calcification–prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013;10:3121–8.
doi: 10.1111/jsm.12334
pubmed: 24119147
Masterson TA, Atuluru P, Zucker I, Molina M, Ibrahim E, Nackeeran S, et al. Collagenase clostridium histolyticum treatment improves degree of curvature in Peyronie’s disease with calcified plaques. Eur Urol Focus. 2023;9:55–9.
doi: 10.1016/j.euf.2022.09.019
pubmed: 36272924
Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J. 1979;11:447–55.
doi: 10.1007/BF01002772
pubmed: 91593
Lattouf R, Younes R, Lutomski D, Naaman N, Godeau G, Senni K, et al. Picrosirius red staining: a useful tool to appraise collagen networks in normal and pathological tissues. J Histochem Cytochem. 2014;62:751–8.
doi: 10.1369/0022155414545787
pubmed: 25023614
Courtoy GE, Leclercq I, Froidure A, Schiano G, Morelle J, Devuyst O, et al. Digital image analysis of picrosirius red staining: a robust method for multi-organ fibrosis quantification and characterization. Biomolecules. 2020;10:1585.
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.
doi: 10.1016/j.juro.2013.01.087
pubmed: 23376148
Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650–6.
doi: 10.1111/bju.13096
pubmed: 25711400
Masterson TA, Rezk A, Ramasamy R. Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie’s disease: a review of the literature. World J Urol. 2020;38:279–85.
doi: 10.1007/s00345-019-02850-3
pubmed: 31250098
Gelbard M, Walsh R, Kaufman JJ. Clostridial collagenase and Peyronie disease. Urology. 1980;15:536.
doi: 10.1016/0090-4295(80)90028-X
pubmed: 6302967
Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res. 1982;10:135–40.
doi: 10.1007/BF00255956
pubmed: 6291216
Del Carlo M, Cole AA, Hart SGE, Levine LA. Comparative analysis of collagen degradation in Peyronie’s disease plaque and Dupuytren’s contracture cord tissues injected with mixed collagenase subtypes. J Urol. 2009;181:279.
doi: 10.1016/S0022-5347(09)60794-1
Levine LA, Schmid TM, Emeigh Hart SG, Tittelbach T, McLane MP, Tursi JP. PD22-03 collagenase clostridium histolyticum degrades type I and III collagen while sparing type IV collagen in vitro in Peyronie’s plaque explants. J Urol. 2014;191:e672–3.
doi: 10.1016/j.juro.2014.02.1854